Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Twinrix Paediatric is a combination vaccine developed by GSK for the prevention of Hepatitis A and Hepatitis B in children and adolescents aged 1 to 15 years. It consists of inactivated Hepatitis A virus (HAV) antigens and recombinant Hepatitis B surface antigens (HBsAg) adsorbed onto aluminum salts. The vaccine stimulates the production of specific antibodies against both viruses, providing long-term immunity. It is typically administered as a three-dose schedule and is indicated for non-immune individuals at risk of infection from both pathogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hepatitis A (inactivated) and hepatitis B (rDNA) vaccine (adsorbed).